EP2077329A1 - Cochon transgénique avec fonction incrétine altérée - Google Patents
Cochon transgénique avec fonction incrétine altérée Download PDFInfo
- Publication number
- EP2077329A1 EP2077329A1 EP08000111A EP08000111A EP2077329A1 EP 2077329 A1 EP2077329 A1 EP 2077329A1 EP 08000111 A EP08000111 A EP 08000111A EP 08000111 A EP08000111 A EP 08000111A EP 2077329 A1 EP2077329 A1 EP 2077329A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- transgenic
- transgenic pig
- cell
- gip
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 117
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical group C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 title claims description 16
- 201000000083 maturity-onset diabetes of the young type 1 Diseases 0.000 claims abstract description 13
- 238000011161 development Methods 0.000 claims abstract description 11
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims abstract description 9
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims abstract description 8
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 claims abstract description 7
- 238000012423 maintenance Methods 0.000 claims abstract description 7
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 58
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 52
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 44
- 210000000496 pancreas Anatomy 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 27
- 206010012601 diabetes mellitus Diseases 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 22
- 210000004153 islets of langerhan Anatomy 0.000 claims description 20
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000000859 incretin Substances 0.000 claims description 14
- 230000001771 impaired effect Effects 0.000 claims description 11
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 10
- 230000000638 stimulation Effects 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 238000007410 oral glucose tolerance test Methods 0.000 claims description 7
- 230000011664 signaling Effects 0.000 claims description 7
- 101001012176 Rattus norvegicus Insulin-2 Proteins 0.000 claims description 6
- 238000011156 evaluation Methods 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 230000008506 pathogenesis Effects 0.000 claims description 6
- 210000001082 somatic cell Anatomy 0.000 claims description 6
- 210000004602 germ cell Anatomy 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 238000012544 monitoring process Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000012512 characterization method Methods 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 101100233149 Sus scrofa INS gene Proteins 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 230000007547 defect Effects 0.000 claims description 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 claims 1
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 claims 1
- 102100035459 Pyruvate dehydrogenase protein X component, mitochondrial Human genes 0.000 claims 1
- 241000282887 Suidae Species 0.000 abstract description 59
- 238000010171 animal model Methods 0.000 abstract description 10
- 102000005962 receptors Human genes 0.000 abstract description 7
- 108020003175 receptors Proteins 0.000 abstract description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 65
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 55
- 239000008103 glucose Substances 0.000 description 52
- 108090001061 Insulin Proteins 0.000 description 32
- 102000004877 Insulin Human genes 0.000 description 32
- 229940125396 insulin Drugs 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 28
- 241000282898 Sus scrofa Species 0.000 description 27
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- 108010011459 Exenatide Proteins 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 12
- 229960001519 exenatide Drugs 0.000 description 12
- 230000003914 insulin secretion Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 238000001990 intravenous administration Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 8
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 6
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000010240 RT-PCR analysis Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000007446 glucose tolerance test Methods 0.000 description 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 4
- 230000002473 insulinotropic effect Effects 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- UOFGSWVZMUXXIY-UHFFFAOYSA-N 1,5-Diphenyl-3-thiocarbazone Chemical compound C=1C=CC=CC=1N=NC(=S)NNC1=CC=CC=C1 UOFGSWVZMUXXIY-UHFFFAOYSA-N 0.000 description 3
- 101150020692 Gipr gene Proteins 0.000 description 3
- 208000002705 Glucose Intolerance Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 238000002695 general anesthesia Methods 0.000 description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 2
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 2
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- VWAUPFMBXBWEQY-ANULTFPQSA-N Altrenogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC=C)C=C3)C3=C21 VWAUPFMBXBWEQY-ANULTFPQSA-N 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010005991 Pork Regular Insulin Proteins 0.000 description 1
- WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101150114644 Rapgef3 gene Proteins 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000012840 University of Wisconsin (UW) solution Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960000971 altrenogest Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000013310 pig model Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000028886 positive regulation of osteoblast proliferation Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940050570 regu-mate Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000029054 response to nutrient Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000007727 signaling mechanism Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000011351 state-of-the-art imaging technique Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/507—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
- A01K2217/056—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to mutation of coding region of the transgene (dominant negative)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Definitions
- the present invention relates to transgenic pigs containing a dominant-negative incretin hormone receptor, namely the dominant-negative human glucose-dependent insulinotropic polypeptide receptor.
- the present invention furthermore relates to uses of these transgenic pigs as clinically relevant animal model systems for studying the development and novel therapies for diabetes mellitus type 2, particularly for the maintenance and expansion of pancreatic ⁇ -cell mass.
- the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are secreted by enteroendocrine cells in response to nutrients like fat and glucose and enhance glucose-induced release of insulin from pancreatic ⁇ -cells (1,2).
- GIP and GLP-1 are both secreted within minutes of nutrient ingestion and facilitate the rapid disposal of ingested nutrients.
- Both peptides share common actions on islet ⁇ -cells acting through structurally distinct yet related receptors. Incretin-receptor activation leads to glucose-dependent enhancement of insulin secretion, induction of ⁇ -cell proliferation, and enhanced resistance to ⁇ -cell apoptosis.
- GIP also promotes energy storage via direct actions on adipose tissue, and enhances bone formation via stimulation of osteoblast proliferation and inhibition of bone resorption.
- GIP and GLP-1 are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4).
- GIP and GLP-1 are mediated through specific 7-transmembrane-domain G-protein coupled receptors, GIPR and GLP-IR, respectively (3).
- GIPR or GLP-1R is coupled to increases in cAMP and intracellular Ca 2+ levels, as well as activation of P1-3K, Epac 2, PKA, PKB, MAPK and phospholipase A2 and finally leads to enhanced exocytosis of insulin-containing granules (4).
- T2D diabetes mellitus type 2
- GIP glucose-dependent insulinotropic polypeptide
- T2D type 2 diabetes mellitus
- the problem is solved by the present invention by providing a transgenic pig.
- the transgenic pig according to the present invention comprises a recombinant nucleic acid encoding a dominant-negative human glucose-dependent insulinotropic polypeptide receptor (hGIPR dn ).
- hGIPR dn a dominant-negative human glucose-dependent insulinotropic polypeptide receptor
- nucleic acid refers to polynucleotides, such as DNA, RNA, modified DNA, modified RNA as well as mixtures thereof.
- a "dominant-negative" GIP receptor refers to a modified GIPR which binds the ligand GIP but is not capable of signal transduction. This dominant-negative receptor competes with the endogenous intact GIP receptor for the ligand GIP and - depending on the level of expression of the dominant-negative receptor - impairs the function of GIP.
- the recombinant nucleic acid encodes a protein which comprises an eight amino acid deletion (residues 319-326) and an amino acid change at residue 340, preferably Ala to Glu, in the third intracellular loop of the hGIPR.
- the recombinant nucleic acid encodes a protein comprising SEQ ID NO: 1 or having SEQ ID NO: 1.
- the recombinant nucleic acid comprises SEQ ID NO: 2, the cDNA sequence corresponding to SEQ ID NO: 1.
- the recombinant nucleic acid encoding hGIPR dn is comprised in a plasmid or viral vector.
- a preferred viral vector is a lentiviral vector.
- the expression vectors can be introduced into somatic cells which will then be used for nuclear transfer to generate cloned transgenic animals.
- the plasmid or viral vector comprises a promoter which allows for expressing the hGIPR in the transgenic pig, preferably allows expression in the pancreatic islets, preferably the ⁇ -cells of the pancreas.
- a preferred promoter is an insulin promoter, more preferably rat insulin 2 gene promoter (RIPII).
- RIPII rat insulin 2 gene promoter
- Further suitable promoters are the pig INS promoter or other promoters which confer expression in the pancreatic islets, such as PDXI.
- promoters with other tissue specificities are used to evaluate the role of GIP receptor function in other GIP target tissues, such as adipose tissue, bone, and brain.
- the recombinant nucleic acid is a lentiviral vector comprising the rat insulin 2 gene promoter (RIPII).
- FIG. 1a A preferred viral construct is shown in Figure 1a .
- the hGIPR dn is expressed in the islets of the pancreas, preferably the ⁇ -cells.
- the hGIPR dn is overexpressed in the islets of the pancreas, preferably the ⁇ -cells, of the transgenic pig compared to wild-type hGIPR.
- the transgenic pig according to the present invention preferably contains the recombinant nucleic acid encoding hGIPR dn is in its germ cells and somatic cells.
- transgenic cell lines can be established by breeding to generate a standardized model system for metabolic research, particularly in the context of diabetes.
- the recombinant nucleic acid encoding hGIPR dn is integrated into the genome of the transgenic pig.
- the dominant-negative GIPR is expressed from an episomal vector.
- the transgenic pig exhibits elevated postprandial glucose levels as well as distinct reduction of initial insulin secretion.
- the transgenic pig exhibits a reduced oral glucose tolerance.
- pancreatic islet and ⁇ -cell mass of the transgenic pig is reduced.
- the volume densities of the islets in the pancreas (Vv (lslet/Pan) ) and of the ⁇ -cells including isolated ⁇ -cells in the pancreas (Vv ( ⁇ -cell/Pan) ) are preferably reduced in GIPR dn transgenic pigs vs. controls. Accordingly, the total islet volume (V (lslet,Pan) ) and the total volume of ⁇ -cells including isolated ⁇ -cells (V ( ⁇ -cell,Pan) ) are smaller in GIPR dn transgenic pigs compared to non-transgenic littermate controls (see also Figures 6b to d) .
- the problem is furthermore solved by the present invention by providing a transgenic cell or transgenic cell line from a transgenic pig of the present invention.
- transgenic cell or cell line is obtained from a transgenic pig of the invention.
- the transgenic cell or cell line is obtained from a germ cell and/or a somatic cell of said transgenic pig.
- transgenic cells or cell lines from the transgenic pigs.
- transgenic cells and/or cell lines are suitable in vitro test systems and can be used for developing autologous cell replacement therapies.
- transgenic cells and/or cell lines can be used to generate a standardized model system for metabolic research, particularly in the context of diabetes.
- transgenic cells and/or cell lines preferably respective somatic cells/cell lines, can also be used to obtain transgenic pigs, such as by cloning strategies.
- the problem is furthermore solved by the present invention by using a transgenic pig according to the present invention as model system for the development and therapy of diabetes mellitus, in particular diabetes mellitus type 2.
- Diabetes mellitus type 2 (formerly called diabetes mellitus type II, non insulin-dependent diabetes (NIDDM), obesity related diabetes, or adult-onset diabetes) according to the present invention refers to a metabolic disorder that is primarily characterized by insulin resistance, relative insulin deficiency, and hyperglycemia. It is rapidly increasing in the developed world, and there is some evidence that this pattern will be followed in much of the rest of the world in coming years. Unlike type 1 diabetes, there is little tendency toward ketoacidosis in type 2 diabetes. One effect that can occur is nonketonic hyperglycemia. Complex and multifactorial metabolic changes lead to damage and function impairment of many organs, most importantly the cardiovascular system in both types. This leads to substantially increased morbidity and mortality in both type 1 and type 2 patients, but the two have quite different origins and treatments despite the similarity in complications.
- the transgenic pigs according to the present invention are a highly suitable animal model system for diabetes mellitus because, as described herein, they exhibit the following clinical symptoms of diabetes mellitus type 2: glucose intolerance and reduction of pancreatic ⁇ -cell mass.
- the transgenic pig model furthermore overcomes the limitations of the mouse model, as e.g. disclosed in DE 198 36 382 C2 .
- a known transgenic mouse contains an altered GIPR which binds GIP but does not induce signalling after binding GIP.
- the transgenic mice expressing the altered GIPR in the ⁇ -cells of the pancreas develop a severe diabetes during the first two months of their lives.
- no specific stimulation studies with GIP or GLP-1 can be performed in the mouse model due to its limited size.
- the unexpected severe phenotype is due to specific inhibition of the GIP effect or due to a mere unspecific disturbance of the ⁇ -cells due to a high level of overexpression of the dominant-negative receptor which may cause - in part - non-specific effects, e.g.
- transgenic pigs of the present invention for the first time a transgenic large animal model with impaired incretin function is established.
- the use preferably comprises the evaluation of the role of impaired GIP signalling in the pathogenesis of diabetes mellitus, in particular diabetes mellitus type 2.
- the use preferably comprises the characterization of the mechanisms by which GIP supports pancreatic islet maintenance in vivo.
- the use preferably comprises the development and evaluation of incretin-based therapeutic strategies of diabetes mellitus, in particular diabetes mellitus type 2.
- diabetes mellitus type 2 in particular diabetes mellitus type 2.
- An example is already provided by the Exendin-4 treatment study, as described herein below. Different treatment regimens can be evaluated with regard to efficacy and safety. Important readouts will be the dynamics of insulin secretion (which can only be determined with the required high resolution in time in a large animal model) and effects on pancreatic islet mass.
- the use preferably comprises the dynamic monitoring of islet mass in diabetes mellitus patients, in particular diabetes mellitus type 2 patients.
- said use comprises the development of novel methods for the dynamic monitoring of islet mass in patients.
- Potential approaches combine specific in vivo labelling of pancreatic islets with state-of-the art imaging technology.
- the problem is furthermore solved by the present invention by providing a method for identifying targets to bypass or overcome aGIPR signaling defect, comprising the utilization of a transgenic pig according to the present invention.
- the problem is furthermore solved by the present invention by providing a method for identifying a compound that modulates the incretin hormone system or complex, comprising:
- Preferred administration routes of a compound are oral, nasal, subcutaneous, intracutaneous, parenteral, transdermal, topical, intravenous, intraarterial, intramuscular, intraperitoneal or combinations thereof.
- Insulin effect refers to a significantly greater insulin stimulatory effect evoked after an oral glucose load than that evoked from an intravenous glucose infusion when plasma glucose concentrations are matched.
- the incretin effect is determined by an oral glucose tolerance test or by stimulation studies with GIP or GLP-1. For more details, see Examples.
- promoters with other tissue specificities are used to evaluate the role of GIP receptor function in other GIP target tissues, such as adipose tissue, bone, and brain. These promoters can also be used in the methods of the invention, such as in order to identify compounds that modulate the incretin hormone system or complex in specific tissues or in a tissue-specific manner.
- transgenic pigs expressing a dominant-negative GIP receptor (GIPR dn ) in the pancreatic islets using lentiviral transgenesis.
- the insulinotropic effect of intravenously administrated GIP was blunted, whereas the GLP-1 receptor agonist Exendin-4 elicited a seven-fold (p ⁇ 0.05) increase in serum insulin in GIPR dn pigs.
- GIPR dn transgenic pigs exhibited significantly elevated glucose levels (p ⁇ 0.05) as well as markedly reduced insulin secretion (p ⁇ 0.01) following oral glucose challenge, but did not develop diabetes mellitus until an age of at least 15 months.
- pancreatic ⁇ -cell mass was reduced by more than 70% in 12-month-old GIPR dn transgenic pigs compared to littermate controls.
- the inventors generated a large animal model mimicking the impaired GIP function in T2D patients.
- a lentiviral vector was cloned that expresses a dominant-negative GIPR (GIPR dn ) under the control of the rat insulin 2 gene promoter (RIPII) ( Figure 1a ).
- the GIPR dn has an eight amino acid deletion (positions 319-326) and an Ala ⁇ Glu exchange at amino acid position 340 in the third intracellular loop, which is essential for signal transduction (11).
- Lentiviral vectors were injected into the perivitelline space of pig zygotes. A total of 113 injected zygotes were transferred laparoscopically into the oviducts of three cycle synchronized recipient gilts (sow 1: 32 zygotes; sow 2: 31 zygotes, sow 3: 50 zygotes) (12). 19 piglets (17% of the transferred zygotes) were born. Southern blot analysis identified 9 founder animals (47.3% of the born animals) carrying one or two lentiviral integrants ( Fig. 1b ), confirming the high efficiency of lentiviral transgenesis in large animals (12).
- pancreatic islets were isolated from transgenic and non-transgenic offspring of both founder boars and analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). Expression of the GIPR dn was detected in the islets of all transgenic animals, but not in the islets of non-transgenic littermates. No signals were obtained from islets of transgenic offspring after omission of the RT step, demonstrating that expressed rather than integrated sequences were detected ( Figure 1c ).
- RT-PCR reverse transcriptase-polymerase chain reaction
- GIPR dn transgenic pigs exhibited a significantly reduced insulin release (52% smaller AUC insulin; p ⁇ 0.05) going along with a decelerated decline of blood glucose levels (10% larger AUC glucose; p ⁇ 0.05) ( Figure 4 ).
- impaired GIPR function causes a general disturbance of insulin secretion and/or alterations in islet structure and/or islet integrity.
- the total pancreas weight did not differ between GIPR dn transgenic pigs and littermate control animals.
- the organs were divided into two portions along a clearly defined anatomical structure ( Figure 5 ).
- the left pancreatic lobe was processed for islet isolation (14).
- the number of islet equivalents was reduced by 93% (p ⁇ 0.05) in pancreas samples of GIPR dn transgenic pigs as compared to control pigs (Table 2).
- Table 1 Table 1
- Type of Pig Total pancreas weight (gram) Pancreas weight wo. left lobe (gram) wt #1 224 114 wt #2 148 80 wt #3 190 100 mean ⁇ SEM 188 ⁇ 22 98 ⁇ 10 tg #1 198 93 tg #2 190 97 tg #3 211 107 mean ⁇ SEM 200 ⁇ 6 99 ⁇ 4 Table 2 .
- pancreatic islet profiles of GIPR dn transgenic pigs appeared to be smaller in size and reduced in number ( Figure 6a ). These findings were confirmed by quantitative stereological investigations (15) of the remnant organ.
- the total islet volume (V (lslet,Pan) ; Figure 6b ) and the total volume of ⁇ -cells including isolated ⁇ -cells (V ( ⁇ -cell,Pan) ; Figure 6c ) were significantly (p ⁇ 0.05) smaller in GIPR dn transgenic pigs compared to non-transgenic littermate controls.
- volume density data not shown
- Figure 6d volume density of isolated ⁇ -cells (single insulin positive cells and small ⁇ -cell clusters containing less than five ⁇ -cell profiles, Vv (iso ⁇ -cell/Pan) , V (iso ⁇ -cell,Pan) ), a parameter indicating islet neogenesis, were not different between the two groups.
- GIPR knockout mice (Gipr - / - ) provided no evidence that GIPR action is required for the maintenance of islet and ⁇ -cell integrity in vivo (16,17) Interestingly, these mice exhibited an increase in relative ⁇ -cell area referring to pancreas area (16), leading to the conclusion that in vivo the function of GIP is primarily restricted to that of an incretin (17).
- the relatively mild phenotype of Gipr - / - mice may result from compensatory mechanisms (17). Islets from Gipr - / - mice were shown to exhibit increased sensitivity to exogenous GLP-1 (16).
- double mutant mice DIRKO
- lacking both GIPR and GLP-1R exhibited more severe glucose intolerance than the individual mutants (18,19), also these double mutant animals did not develop diabetes mellitus.
- RIPII-GIPR dn transgenic mice develop massive early-onset diabetes mellitus with marked structural changes of the pancreatic islets (11), precluding long-term studies as to the role of GIP signaling for islet maintenance in the absence of glucose toxicity.
- the massive changes observed in GIPR dn transgenic mice were unexpected and are possibly due to a high level of overexpression of the dominant-negative preceptor which may cause - in part - non-specific effects, e.g. by squelching of G-proteins.
- GIPR dn transgenic pigs represent a more clinically relevant animal model for a plethora of applications in basic and translational research including the detailed characterization of mechanisms by which GIP supports islet maintenance in vivo, the development and preclinical evaluation of incretin-based therapies (reviewed in 20) as well as the development of novel methods for dynamic monitoring of islet mass in T2D patients (21).
- the expression cassette consisting of the rat insulin 2 promoter (RIPII) and the cDNA of a dominant-negative human glucose-dependent insulinotropic polypeptide receptor (hGIPR dn ) was described previously (11) and cloned into the lentiviral vector LV-pGFP (22) via the Cla I and Sal I restriction sites. Recombinant lentivirus was produced as previously described (22).
- the respective cDNA sequence is shown in SEQ ID NO: 2.
- the respective amino acid sequence is shown in SEQ ID NO: 1.
- Zygotes were collected from 6-month old superovulated and artificially inseminated gilts after slaughter as previously described (12). As recipients six-month-old estrus-synchronized gilts were used. Pig embryo transfers were performed laparoscopically as previously described (23).
- Offspring were genotyped by PCR using DNA prepared from ear tips by application of the Wizard DNA Extraction Kit (Clontech, Mountain View, USA).
- Transgene-specific primers were used: sense: 5'-TTT TTA TCC GCA TTC TTA CAC GG-3' [SEQ ID NO: 3] and antisense 5'-ATC TTC CTC AGC TCC TTC CAG G-3' [SEQ ID NO: 4].
- genomic DNA (aliquots of 8 ⁇ g) extracted from EDTA blood using the Blood and Cell Culture DNA Midi kit (Qiagen, Hilden, Germany), was digested with the restriction enzyme Apa I and hybridized with a 32 P-labeled probe directed towards the RIPII promoter sequence.
- transgene specific primers sense: 5'-TTT TTA TCC GCA TTC TTA CAC GG-3' [SEQ ID NO: 3] and antisense 5'-ATC TTC CTC AGC TCC TTC CAG G-3' [SEQ ID NO: 4].
- Example 5 Non-surgical and surgical implantation of central venous catheters
- the OGTT was performed in 5-month-old non-restrained, freely moving animals. After an 18-h overnight fast, animals were fed 2 g/kg BW glucose (25) mixed with 100g of commercial pig fodder (Deuka porfina U, Deuka, Düsseldorf, Germany). The meal was eaten from a bowl under supervision. Blood samples were obtained from the jugular vein catheter at -15, -5, 0, 15, 30, 45, 60, 90, 120, 150 and 180 minutes relative to the glucose load. Blood glucose was immediately determined using a Precision ® Xceed TM Glucometer (Abbott, Wiesbaden, Germany). For serum insulin measurements see below.
- the GIP/Exendin-4 stimulation test was performed in 7-months-old (28-36 weeks) non-restrained freely moving animals. Following an 18-hour fasting period, 0.5 g glucose/kg BW were administered intravenously as a bolus of concentrated 50% glucose solution (26). After three minutes 20 pmol/kg BW of synthetic porcine GIP (Bachem, Weil am Rhein, Germany) or 10 pmol/kg BW of synthetic Exendin-4 (Bachem) were administered intravenously. Blood samples were collected -15, 0, 1, 3, 6, 9, 11, 13, 18, 23, 28, 33, 48 and 60 minutes relative to the glucose load.
- Serum glucose levels were determined using an AU 400 autoanalyzer (Olympus, Hamburg, Germany) while serum insulin levels were measured in duplicate using a porcine insulin radioimmunoassay (RIA) kit (Millipore, Billerica, USA) according to the manufacturer's instructions.
- RIA porcine insulin radioimmunoassay
- Example 8 lntravenous glucose tolerance test (IVGTT)
- the IVGTT was performed in pigs at 10 months (45 weeks ⁇ 2 weeks) of age. After an 18-h overnight fast, a bolus injection of concentrated 50% glucose solution (0.5 g glucose/kg BW) (26) was administered through the central venous catheter. Blood was collected at -15, -5, 0, 1, 3, 5, 10, 20, 30, 40, 50, 60, 120 and 180 minutes relative to the glucose load. Serum glucose and serum insulin levels were determined as described above (Example 7).
- Example 9 Pancreas preparation and islet isolation
- Pancreatic islets were isolated from three 12- to 13-month-old GIPR dn transgenic pigs and three littermate control animals ( ⁇ 220 kg). After precise explantation of the pancreata in toto, the major pancreatic duct was canulated using a Cavafix ® Certo 18G catheter (B. Braun). Following separation from the rest of the organ along a clearly defined anatomical structure (see Figure 5 ), the left pancreatic lobe was distended with University of Wisconsin (UW) solution containing 4 PZ units NB8 collagenase (Nordmark, Uetersen, Germany) per gram of organ and 0.7 DMC units neutral protease (Nordmark).
- UW University of Wisconsin
- pancreata were digested using a modification of the half-automated digestion-filtration method as previously described (27). Purification of the isolated islets was performed with the discontinuous OptiPrep TM density gradient (Progen, Heidelberg, Germany) in the COBE 2991 cell processor (COBE Inc., Colorado, USA) (28). Purified islets were cultured in HAM'S F12 culture medium (Cell Concepts, Umkirch, Germany; supplemented with 10% FCS, 1% amphotericine B, 1% L-glutamine, 1% ampicilline/gentamycine and 50 mM nicotinamide) at 24°C and 5% CO 2 in air.
- HAM'S F12 culture medium Cell Concepts, Umkirch, Germany; supplemented with 10% FCS, 1% amphotericine B, 1% L-glutamine, 1% ampicilline/gentamycine and 50 mM nicotinamide
- Islet numbers were determined using dithizone (DTZ) stained islet samples 29 (triplicates) which were counted under an Axiovert 25 microscope (Zeiss, Oberkochen, Germany) with a calibrated grid in the eyepiece, grouped into size categories and converted into islet equivalents (IEQ), i.e., islets with an average diameter of 150 ⁇ m. Purity of the islets was estimated by two independent individuals using dithizone stained samples of the islet suspension (triplicates).
- DTZ dithizone stained islet samples 29 (triplicates) which were counted under an Axiovert 25 microscope (Zeiss, Oberkochen, Germany) with a calibrated grid in the eyepiece, grouped into size categories and converted into islet equivalents (IEQ), i.e., islets with an average diameter of 150 ⁇ m. Purity of the islets was estimated by two independent individuals using dithizone stained samples of the islet suspension (triplicates).
- islet vitality For determination of islet vitality, an aliquot of the islet suspension was stained with freshly prepared fluorescein diacetate (FDA, Sigma) and propidium iodide solution (PI, Sigma) and then estimated by two independent individuals using a BX50 fluorescence microscope (Olympus).
- FDA fluorescein diacetate
- PI propidium iodide solution
- pancreas was cut into 1 cm thick slices. Slices were tilted to their left side and covered by a 1 cm 2 point-counting grid.
- tissue blocks were selected by systematic random sampling, fixed in 10% neutral buffered formalin, routinely processed and embedded in paraffin. From a series of approximately 4 ⁇ m thick sections, one section was stained with hematoxylin and eosin (H&E) and the following section was used for immunohistochemistry.
- the volume of the pancreas (V (Pan) ) before embedding was calculated by the quotient of the pancreas weight and the specific weight of the pig pancreas (1.07 g/cm 3 ).
- the specific weight was determined by the submersion method (30).
- the indirect immunoperoxidase technique was applied to localize insulin containing cells as previously described (11).
- a polyclonal guinea pig anti-porcine insulin antibody (dilution 1:1,000) (Dako Cytomation, Hamburg, Germany) as well as horseradish peroxidase conjugated polyclonal rabbit anti-guinea pig IgG (dilution 1:50 containing 5% (vol/vol) porcine serum) were used.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08000111A EP2077329A1 (fr) | 2008-01-04 | 2008-01-04 | Cochon transgénique avec fonction incrétine altérée |
US12/348,294 US7919673B2 (en) | 2008-01-04 | 2009-01-04 | Transgenic pig with altered incretin function |
EP09000044A EP2077330A1 (fr) | 2008-01-04 | 2009-01-05 | Cochon transgénique avec fonction incrétine altérée et ses utilisations pour l'étude du diabète |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08000111A EP2077329A1 (fr) | 2008-01-04 | 2008-01-04 | Cochon transgénique avec fonction incrétine altérée |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2077329A1 true EP2077329A1 (fr) | 2009-07-08 |
Family
ID=39432814
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08000111A Withdrawn EP2077329A1 (fr) | 2008-01-04 | 2008-01-04 | Cochon transgénique avec fonction incrétine altérée |
EP09000044A Withdrawn EP2077330A1 (fr) | 2008-01-04 | 2009-01-05 | Cochon transgénique avec fonction incrétine altérée et ses utilisations pour l'étude du diabète |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09000044A Withdrawn EP2077330A1 (fr) | 2008-01-04 | 2009-01-05 | Cochon transgénique avec fonction incrétine altérée et ses utilisations pour l'étude du diabète |
Country Status (2)
Country | Link |
---|---|
US (1) | US7919673B2 (fr) |
EP (2) | EP2077329A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110305872A (zh) * | 2019-07-17 | 2019-10-08 | 中国农业科学院北京畜牧兽医研究所 | 小型猪2型糖尿病模型的构建方法及应用 |
US20210100225A1 (en) * | 2015-10-08 | 2021-04-08 | President And Fellows Of Harvard College | Multiplexed Genome Editing |
US12058986B2 (en) | 2017-04-20 | 2024-08-13 | Egenesis, Inc. | Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140112958A1 (en) | 2012-10-24 | 2014-04-24 | Mwm Biomodels Gmbh | Pancreatic islets of transgenic LEA29Y animals for treating diabetes |
US10126220B2 (en) * | 2013-07-22 | 2018-11-13 | National Oilwell Varco, L.P. | Systems and methods for determining specific gravity and minerological properties of a particle |
ES2784643T3 (es) | 2014-08-28 | 2020-09-29 | Univ Aarhus | Modelo de cerdo para la diabetes |
CN113699116A (zh) | 2014-12-10 | 2021-11-26 | 明尼苏达大学董事会 | 用于治疗疾病的遗传修饰的细胞、组织和器官 |
CN106222176A (zh) * | 2016-08-08 | 2016-12-14 | 中国农业科学院深圳农业基因组研究所 | 一种dna分子及其在制备糖尿病鼠模型中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0979872A1 (fr) * | 1998-08-11 | 2000-02-16 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Animal modèle pour le dévelopement et la thérapie du diabète mellitus |
-
2008
- 2008-01-04 EP EP08000111A patent/EP2077329A1/fr not_active Withdrawn
-
2009
- 2009-01-04 US US12/348,294 patent/US7919673B2/en not_active Expired - Fee Related
- 2009-01-05 EP EP09000044A patent/EP2077330A1/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0979872A1 (fr) * | 1998-08-11 | 2000-02-16 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Animal modèle pour le dévelopement et la thérapie du diabète mellitus |
DE19836382C2 (de) | 1998-08-11 | 2000-12-07 | Gsf Forschungszentrum Umwelt | Neues Tiermodell zur Entstehung und Therapie von Diabetes Mellitus |
Non-Patent Citations (34)
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210100225A1 (en) * | 2015-10-08 | 2021-04-08 | President And Fellows Of Harvard College | Multiplexed Genome Editing |
US12058986B2 (en) | 2017-04-20 | 2024-08-13 | Egenesis, Inc. | Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements |
CN110305872A (zh) * | 2019-07-17 | 2019-10-08 | 中国农业科学院北京畜牧兽医研究所 | 小型猪2型糖尿病模型的构建方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
EP2077330A1 (fr) | 2009-07-08 |
US7919673B2 (en) | 2011-04-05 |
US20090228993A1 (en) | 2009-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2077329A1 (fr) | Cochon transgénique avec fonction incrétine altérée | |
Hennige et al. | Upregulation of insulin receptor substrate-2 in pancreatic β cells prevents diabetes | |
Renner et al. | Glucose intolerance and reduced proliferation of pancreatic β-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function | |
George et al. | β cell expression of IGF-I leads to recovery from type 1 diabetes | |
Gray et al. | Targeted disruption of the pituitary adenylate cyclase-activating polypeptide gene results in early postnatal death associated with dysfunction of lipid and carbohydrate metabolism | |
Tsunekawa et al. | Protection of pancreatic β-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies | |
EP2389955A1 (fr) | Modèle animal et méthode d'obtention d'un tel modèle | |
Herbach et al. | Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell development | |
US20210040459A1 (en) | Cells genetically modified to comprise pancreatic islet glucokinase and uses thereof | |
NZ565337A (en) | Using cytosine deaminases to diminish retroelement transfer from pigs to humans | |
Lu et al. | Activation of the Reg family genes by pancreatic-specific IGF-I gene deficiency and after streptozotocin-induced diabetes in mouse pancreas | |
US20090186946A1 (en) | Genetically Modified Animal and Use Thereof | |
EP0914419A1 (fr) | Mammiferes transgeniques capables d'exprimer le facteur d'inhibition de la leucemie (lif) | |
EP1980148B1 (fr) | Animal genetiquement modifie et son utilisation | |
Liu | Does IGF-I stimulate pancreatic islet cell growth? | |
JP5030792B2 (ja) | 糖尿病モデル動物 | |
Kumar et al. | Transgenic overexpression of cardiac actin in the mouse heart suggests coregulation of cardiac, skeletal and vascular actin expression | |
US20090214482A1 (en) | Transgenic Mammals Expressing Human Preproinsulin | |
Shirneshan et al. | Directed overexpression of insulin in Leydig cells causes a progressive loss of germ cells | |
Krakowski et al. | IFN-γ overexpression within the pancreas is not sufficient to rescue Pax4, Pax6, and Pdx-1 mutant mice from death | |
Bachmann | Establishment and characterization of a size-reduced, diabetic pig model by minipig crossbreeding | |
Renner | Transgenic pigs expressing a dominant-negative glucose-dependent insulinotropic polypeptide receptor: a novel animal model for studying the consequences of impaired incretin hormone function | |
Wogensen et al. | Functional effects of transgenic expression of cholera toxin in pancreatic beta-cells | |
Horseman | Prolactin and the Prolactin Receptor | |
Ji-Won et al. | Control of atuoimmune diabetes in NOD mice by GAD expression or Suppression in Beta cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
AKX | Designation fees paid | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100109 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: 8566 |